JP2011525535A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525535A5
JP2011525535A5 JP2011516533A JP2011516533A JP2011525535A5 JP 2011525535 A5 JP2011525535 A5 JP 2011525535A5 JP 2011516533 A JP2011516533 A JP 2011516533A JP 2011516533 A JP2011516533 A JP 2011516533A JP 2011525535 A5 JP2011525535 A5 JP 2011525535A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
hetero
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011516533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048299 external-priority patent/WO2010008847A2/en
Publication of JP2011525535A publication Critical patent/JP2011525535A/ja
Publication of JP2011525535A5 publication Critical patent/JP2011525535A5/ja
Withdrawn legal-status Critical Current

Links

JP2011516533A 2008-06-24 2009-06-23 PI3K/mTOR阻害剤 Withdrawn JP2011525535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7513408P 2008-06-24 2008-06-24
US61/075,134 2008-06-24
PCT/US2009/048299 WO2010008847A2 (en) 2008-06-24 2009-06-23 Pi3k/m tor inhibitors

Publications (2)

Publication Number Publication Date
JP2011525535A JP2011525535A (ja) 2011-09-22
JP2011525535A5 true JP2011525535A5 (https=) 2012-08-09

Family

ID=41550954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516533A Withdrawn JP2011525535A (ja) 2008-06-24 2009-06-23 PI3K/mTOR阻害剤

Country Status (4)

Country Link
US (1) US20110178070A1 (https=)
EP (2) EP2303886A2 (https=)
JP (1) JP2011525535A (https=)
WO (1) WO2010008847A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2440058A4 (en) * 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US20110319405A1 (en) * 2010-06-28 2011-12-29 The Board Of Trustees Of The Leland Stanford Junior University Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
AP2014007595A0 (en) 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
HK1202333A1 (en) * 2011-11-11 2015-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2013235479A1 (en) * 2012-03-23 2014-10-02 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via PI3K inhibition
SI2897644T1 (sl) * 2012-09-20 2018-10-30 Novartis Ag Farmacevtska kombinacija, ki obsega fosfatidilinozitol 3-kinazni inhibitor in aromatazni inhibitor
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9073946B2 (en) 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
US20140275560A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles and intermediates therefrom
WO2014158646A1 (en) * 2013-03-13 2014-10-02 Dow Agrosciences Llc Improved process for the preparation of certain triaryl rhamnose carbamates
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
CN105130973B (zh) * 2014-05-26 2018-05-01 海南国瑞堂中药制药有限公司 5-吡啶基-2-氨基-苯并[d]噁唑衍生物及其制备方法和用途
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11116754B2 (en) 2015-11-13 2021-09-14 The Trustees Of Columbia University In The City Of New York Inhibition of TOR complex 2 increases immunity against bacterial infection
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
WO2018017435A1 (en) * 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
DK3600270T3 (da) * 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
MX2019015057A (es) * 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
WO2018237370A1 (en) * 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
CN109111464B (zh) * 2017-06-23 2021-02-26 爱科诺生物医药股份有限公司 一种具有细胞坏死抑制活性的杂环化合物
US10669246B2 (en) 2017-10-02 2020-06-02 1ST Biotherapeutics, Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
IL279219B2 (en) 2018-06-08 2024-08-01 Ac Immune Sa Novel compounds for diagnosis
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN109320511A (zh) * 2018-10-26 2019-02-12 广安凯特制药有限公司 一种高纯度帕博西尼中间体产品及其制备方法
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7のインヒビターおよびそれらの使用
US11098044B2 (en) 2019-02-22 2021-08-24 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
KR20210126146A (ko) * 2019-03-07 2021-10-19 주식회사 퍼스트바이오테라퓨틱스 Pet 방사선추적자로서의 [18f]-라벨링된 벤조티아졸 유도체
US10385046B1 (en) 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
JP7604387B2 (ja) * 2019-03-28 2024-12-23 ファースト・バイオセラピューティクス・インコーポレイテッド ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
WO2021242955A1 (en) * 2020-05-28 2021-12-02 Senda Biosciences, Inc. Fused azole heterocycles as ahr antagonists
EP4200299B1 (en) * 2020-08-21 2026-03-18 1st Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
JP7773233B2 (ja) 2020-08-21 2025-11-19 ファースト・バイオセラピューティクス・インコーポレイテッド Pet放射性トレーサとしての[18f]標識イミダゾピリジン誘導体
IL301244A (en) * 2020-09-28 2023-05-01 1St Biotherapeutics Inc INDOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING THEM
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
CZ310416B6 (cs) * 2023-12-15 2025-05-28 Univerzita Hradec Králové 1-(3-Chlor-4-hydroxyfenyl)-3-(6-((trifluormethyl)thio)benzo[d]thiazol-2-yl)močovina pro použití pro léčbu rakoviny

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JP2003521543A (ja) * 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー 2−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US7029729B2 (en) * 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
JP2006248948A (ja) * 2005-03-09 2006-09-21 Dainippon Printing Co Ltd 液晶性有機化合物、有機半導体構造物及び有機半導体装置並びに液晶性有機化合物の製造方法
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
AU2008282728B2 (en) * 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
AR071523A1 (es) * 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase

Similar Documents

Publication Publication Date Title
JP2011525535A5 (https=)
JP2011503099A5 (https=)
JP2012140432A5 (https=)
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
JP2017533968A5 (https=)
JP2016525075A5 (https=)
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
HRP20180483T1 (hr) Spoj kinolona
JP2013535460A5 (https=)
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2011519854A5 (https=)
RU2018123779A (ru) Новые соединения
JP2014525420A5 (https=)
JP2011520792A5 (https=)
JP2014512406A5 (https=)
JP2013533879A5 (https=)
JP2016514719A5 (https=)
SI2925757T1 (en) Compounds and compositions for the treatment of parasitic diseases
JP2011519374A5 (https=)
JP2011521911A5 (https=)
RU2012129168A (ru) Производные оксазина
JP2013530176A5 (https=)
JP2015531366A5 (https=)
JP2016540803A5 (https=)
JP2009535307A5 (https=)